COST-EFFECTIVENESS OF ADDING EZETIMIBE TO ATORVASTATIN THERAPY IN PORTUGAL

被引：0
|
作者：
Laires, P. [1 ]
Tun-Ying, H. [2 ]
Ambegaonkar, B. M. [3 ]
Davies, G. M. [4 ]
机构：
[1] Merck Sharp & Dohme Ltd, Oeiras, Portugal
[2] Merck Sharp & Dohme Ltd, Whitehouse Stn, NJ USA
[3] Merck & Co Inc, Whitehouse Stn, NJ USA
[4] Merck & Co Inc, Upper Gwynedd, PA USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.995
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A371 / A371
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR ADVANCED MELANOMA TREATMENT IN PORTUGAL
    Silva Miguel, L.
    Vargas Lopes, F.
    Pinheiro, B.
    Wang, J.
    Xu, R.
    Pellissier, J.
    Laires, P. A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A729 - A729
  • [32] COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN SWEDEN
    Thurston, S.
    Webb, C.
    Borgman, B.
    Van Hout, B.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A166 - A167
  • [33] COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE NETHERLANDS
    Thurston, S. J.
    Webb, K.
    Ong, S.
    Meerding, W. J.
    van Hout, B. A.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A335 - A335
  • [34] Cost-effectiveness analysis of atorvastatin compared to simvastatin treatment in Greece
    Yfantopoulos, J.
    Papagiannopoulou, V.
    [J]. ARCHIVES OF HELLENIC MEDICINE, 2007, 24 (05):
  • [35] Cost-effectiveness of rosuvastatin and ezetimibe/simvastatin in patients with dyslipidemia in Mexico City
    Gomez-Briceno, G. A.
    Mino, D.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A44 - A44
  • [36] Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
    Schlackow, Iryna
    Kent, Seamus
    Herrington, William
    Emberson, Jonathan
    Haynes, Richard
    Reith, Christina
    Collins, Rory
    Landray, Martin J.
    Gray, Alastair
    Baigent, Colin
    Mihaylova, Borislava
    Baxter, A.
    Young, A.
    Hill, M.
    Knott, C.
    Cass, A.
    Feldt-Rasmussen, B.
    Fellstrom, B.
    Grobbee, D. E.
    Gronhagen-Riska, C.
    Haas, M.
    Holdaas, H.
    Hooi, L. S.
    Jiang, L.
    Kasiske, B.
    Krairittichai, U.
    Levin, A.
    Massy, Z. A.
    Tesar, V.
    Walker, R.
    Wanner, C.
    Wheeler, D. C.
    Wiecek, A.
    Dasgupta, T.
    Herrington, W.
    Lewis, D.
    Mafham, M.
    Majoni, W.
    Reith, C.
    Emberson, J.
    Parish, S.
    Simpson, D.
    Strony, J.
    Musliner, T.
    Agodoa, L.
    Armitage, J.
    Chen, Z.
    Craig, J.
    de Zeeuw, D.
    Gaziano, J. M.
    [J]. KIDNEY INTERNATIONAL, 2019, 96 (01) : 170 - 179
  • [37] Adding Cost-effectiveness to Define Low-Value Care
    Pandya, Ankur
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (19): : 1977 - 1978
  • [38] Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study
    Slot, Matilde
    Rasmussen, Thomas Bojer
    Norgaard, Mette
    Larsen, Carsten Schade
    Ehlers, Lars Holger
    [J]. PHARMACOECONOMICS-OPEN, 2024,
  • [39] Cost-effectiveness of Ezetimibe co-administration in CHD patients not at goal with current statin therapy in Hong Kong
    Lee, VW
    Chan, WK
    Alemao, E
    Yin, D
    Cook, JR
    Lee, BS
    Chong, AC
    Tomlinson, B
    Wong, JC
    Lee, KKC
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 268 - 268
  • [40] Cost-effectiveness of cardiac resynchronization therapy
    Ward, Alexandra
    Guo, Shien
    Caro, J. Jaime
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (06) : 1283 - 1283
12345